New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2021, WHO guidelines for malaria, 16 February 2021.
View latest version (2021)Bibliographic Info
GuidelineGuidelines for the Treatment of Malaria
Year of Publication2010
Issuing Institution
Recommendation
Status
Retired
Recommended in favor
Strong
Certainty of evidence
High
Dihydroartemisinin plus piperaquine (DHA+PPQ) is an option for the first-line treatment of uncomplicated P. falciparum malaria worldwide.
Notes and Remarks
- 1)the ACT options now recommended for treatment of uncomplicated falciparum malaria in alphabetical order are: ■ artemether plus lumefantrine, ■ artesunate plus amodiaquine, ■ artesunate plus mefloquine, ■ artesunate plus sulfadoxine-pyrimethamine,7 ■ dihydroartemisinin plus piperaquine.
- 2)Addition of a single dose primaquine (0.75 mg/kg) to ACT treatment for uncomplicated falciparum malaria as an antigametocyte medicine, particularly as a component of pre-elimination or an elimination programme.